Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network

References

• Fu K, Weisenburger DD, Greiner TC, . Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005;106:4315–4321.
   PubMed Web of Science ®Google Scholar
• Salaverria I, Zettl A, Bea S, . Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 2007;25:1216–1222.
   PubMed Web of Science ®Google Scholar
• Hartmann EM, Campo E, Wright G, . Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood 2010;116:953–961.
   PubMed Web of Science ®Google Scholar
• Wlodarska I, Dierickx D, Vanhentenrijk V, . Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood 2008;111:5683–5690.
   PubMed Web of Science ®Google Scholar
• Mozos A, Royo C, Hartmann E, . SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009;94:1555–1562.
   PubMed Web of Science ®Google Scholar
• Quintanilla-Martinez L, Slotta-Huspenina J, Koch I, . Differential diagnosis of cyclin D2+ mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-PCR. Haematologica 2009;94:1595–1598.
   PubMed Web of Science ®Google Scholar
• Determann O, Hoster E, Ott G, . Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008;111:2385–2387.
   PubMed Web of Science ®Google Scholar
• Klapper W, Hoster E, Determann O, . Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop 2009;2:103–111.
   PubMedGoogle Scholar
• Jares P, Campo E. Advances in the understanding of mantle cell lymphoma. Br J Haematol 2008;142:149–165.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Wiestner A, . The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3: 185–197.
   PubMed Web of Science ®Google Scholar
• Hermine O, Hoster E, Walewski J, . Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high-dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to six courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: Results of the MCL younger trial of the European Mantle Cell Lymphoma Network (MCLnet). Blood 2010;116(Suppl. 1); Abstract 110.
   Google Scholar
• Jardin F, Picquenot JM, Parmentier F, . Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value. Br J Haematol 2009;146: 607–618.
   PubMed Web of Science ®Google Scholar
• Delfau-Larue MH, Hoster E, Jardin F, . High dose aracytine in induction might counteract the adverse prognostic value of gene copy number alteration in autografted MCL patients. A EUMCL network study. Ann Oncol 2011;22(Suppl. 4): Abstract 234.
   Google Scholar
• Pérez-Galán P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011;117:26–38.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Gupta M. Signal transduction inhibitor therapy for lymphoma. Hematology Am Soc Hematol Educ Program 2010: 265–270.
   PubMedGoogle Scholar
• Castillo JJ, Furman M, Winer ES. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs 2012;21:15–22.
   PubMed Web of Science ®Google Scholar
• Lannutti BJ, Meadows SA, Herman SE, . CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117:591–594.
   PubMed Web of Science ®Google Scholar
• Hess G, Herbrecht R, Romaguera J, . Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:3822–3829.
   PubMed Web of Science ®Google Scholar
• Boehme V, Schmitz N, Zeynalova S, . CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009;113:3896–3902.
   PubMed Web of Science ®Google Scholar
• Ferrer A, Bosch F, Villamor N, . Central nervous system involvement in mantle cell lymphoma. Anna Oncol 2008;19:135–141.
   PubMed Web of Science ®Google Scholar
• Oinonen R, Franssila K, Elonen E. Central nervous system involvement in patients with mantle cell lymphoma. Ann Hematol 1999;78:145–149.
   PubMed Web of Science ®Google Scholar
• Valdez R, Kroft SH, Ross CW, . Cerebrospinal fluid involvement in mantle cell lymphoma. Mod Pathol 2002;15:1073–1079.
   PubMed Web of Science ®Google Scholar
• Gill S, Herbert KE, Prince HM, . Mantle cell lymphoma with central nervous system involvement: frequency and clinical features. Br J Haematol 2009;147:83–88.
   PubMed Web of Science ®Google Scholar
• Martin P, Chadburn A, Christos P, . Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009;27:1209–1213.
   PubMed Web of Science ®Google Scholar
• Navarro A, Campo E. New perspective and challanges in the understanding of mantle cell lymphoma. Ann Oncol 2011;22(Suppl. 4): iv32–iv35.
   Google Scholar
• Wang X, Asplund AC, Porwit A, . The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival. Br J Haematol 2008;143:248–252.
   PubMed Web of Science ®Google Scholar
• Fernandez V, Salamero O, Espinet B, . Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010;70:1408–1418.
   PubMed Web of Science ®Google Scholar
• Milpied N, Gaillard F, Moreau P, . High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Bone Marrow Transplant 1998;22:645–650.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Vose JM, Zinzani PL, . An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011;22:1622–1627.
   PubMed Web of Science ®Google Scholar
• Gianni AM, Magni M, Martelli M, . Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (r-HDS regimen). Blood 2003;102:749–755
   PubMed Web of Science ®Google Scholar
• Pott C, Hoster E, Delfau-Larue MH, . Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 2010;115:3215–3223.
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, Doorduijn JK. Treatment of elderly patients with mantle cell lymphoma. Semin Hematol 2011;48: 208–213.
   PubMed Web of Science ®Google Scholar
• van der Velden VH, Panzer-Grümayer ER, Cazzaniga G, . Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia 2007;21:706–713.
   PubMed Web of Science ®Google Scholar
• Smith SM, van Besien K, Karrison T, . Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol 2010;28:4740–4746.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Tang H, Kurtin PJ, . Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 2011;12:361–368.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Al-Batran SE, Kim SZ, . Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005;23:3383–3389.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, von Gruenhagen U, Niederle N, . Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas. First interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2007;110(Suppl. 1): Abstract 385.
   Google Scholar
• Visco C, Castegnaro S, Chieregato K, . The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. Blood Cells Mol Dis 2012;48:68–75.
   PubMed Web of Science ®Google Scholar
• Visco C, Zambello R, Paolini R, . Rituximab, bendamustine and cytarabine (R-BAC) is a very active regimen in patients with mantle cell lymphoma not eligible for intensive chemotherapy or autologous transplant. Blood 2011;118(Suppl. 1): Abstract 2677.
   PubMed Web of Science ®Google Scholar
• Kaufmann H, Raderer M, Wohrer S, . Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004;104:2269–2271.
   PubMed Web of Science ®Google Scholar
• Wang M, Fayad L, Wagner-Bartak N, . Oral lenalidomide plus 4 doses of rituximab induced prolonged remissions in relapsed/refractory mantle cell lymphoma: a completed phase I/II clinical trial. Ann Oncol 2011;22(Suppl. 4): Abstract 109.
   Google Scholar
• Harel S, Bachy E, Haioun C, . Efficacy and safety of thalidomide in mantle cell lymphoma: results of the French ATU program. Blood 2010;118(Suppl. 1): Abstract 4501.
   PubMed Web of Science ®Google Scholar